Sugi Predict

Sugi Predict / Compounds / SCHEMBL2941193

SCHEMBL2941193

SCHEMBL2941193

CC1C(=O)N(c2ccc(OC(F)(F)F)cc2)C(=O)N1Cc1ccncc1N1CCN(C)CC1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.38
▸ TRPV4 Q9HBA0 4/20 0.37
▸ SMO Q99835 2/20 0.35
▸ MAP4K1 Q92918 1/20 0.35
▸ PRKAA2 P54646 1/20 0.34
▸ HCRTR1 O43613 4/20 0.34
▸ HCRTR2 O43614 4/20 0.34
▸ CYP3A4 P08684 2/20 0.34
▸ GPR139 Q6DWJ6 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ SCN5A Q14524 1/20 0.33
▸ SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939878 0.92 IGF1R (0.42) IGF1RSMOHCRTR1HCRTR2CYP3A4
SCHEMBL2936089 0.90 IGF1R (0.41) IGF1RALDH1A1SMOHCRTR1HCRTR2
SCHEMBL2940484 0.86 IGF1R (0.42) IGF1RTRPV4SMOCYP3A4NTRK1
SCHEMBL2940106 0.85 EPHX2 (0.40) IGF1RALDH1A1PRKAA2
SCHEMBL2938026 0.83 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2CYP3A4
SCHEMBL2941220 0.83 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2CYP3A4
SCHEMBL2938341 0.83 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2CYP3A4
SCHEMBL2942595 0.83 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2CYP3A4
SCHEMBL3730324 0.82 IGF1R (0.43) IGF1RSMOHCRTR1HCRTR2CYP3A4
SCHEMBL2940391 0.82 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885ALDH1A1 3413/4885TRPV4 4699/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885ALDH1A1 2827/4885TRPV4 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.